Nolan Campbell

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Pei‐Ran Ho, Harold Koendgen, Nolan Campbell et al. · The Lancet Neurology · 2017 · 322 citations

Life Sciences, Neurology, Neuroscience +14

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Lana Zhovtis Ryerson, John Foley, Ih Chang et al. · Neurology · 2019 · 194 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl et al. · Journal of Neurology Neurosurgery & Psychiatry · 2020 · 164 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +16

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 110 citations

Medicine, Pharmacology, Pharmacotherapy +11